prostate cancer

Why Are Mammogram Guidelines Conflicting? 

When women are fully informed about the risks and benefits of mammograms, 70 percent may choose not to get screened. You may be in that 30 percent who opts to get a mammogram and absolutely have the right to decide for yourself.  “For nearly a century, public health organizations, professional associations, patient advocacy groups, academics, and clinicians largely viewed cancer screening as a simple, …

Why Are Mammogram Guidelines Conflicting?  Read More »

PROpel study backs Lynparza combo in first-line prostate cancer

AstraZeneca and Merck & Co PARP inhibitor Lynparza is already used to treat prostate cancer associated with a specific genetic mutation, but could see the drug’s use broadened after a positive phase 3 trial. The results of the PROpel study showed that a combination of Lynparza (olaparib) and Johnson & Johnson’s hormonal therapy Zytiga (abiraterone …

PROpel study backs Lynparza combo in first-line prostate cancer Read More »

FDA clears AI-powered prostate cancer detection software

Software that can help pathologists detect prostate cancer from slides of biopsies more effectively has been approved by the FDA. The software – called Paige Prostate – is the first artificial intelligence-based to be approved by the FDA for this purpose, according to the US regulator. It is used to screen for signs of cancer …

FDA clears AI-powered prostate cancer detection software Read More »

NICE changes its mind on J&J’s Erleada in prostate cancer

NICE has reversed its position on Johnson & Johnson’s oral prostate cancer therapy Erleada in patients with hormone-relapsed or hormone sensitive tumours, backing NHS use of the drug. The change of heart comes after J&J’s Janssen pharma unit offered an improved discount on Erleada (apalutamide), according to the cost-effectiveness watchdog in its final appraisal determination, …

NICE changes its mind on J&J’s Erleada in prostate cancer Read More »

NICE second Zytiga rejection ‘shows need for flexible pricing models’

NICE has stuck with its original decision to reject NHS funding for Johnson & Johnson’s Zytiga as a treatment for men with newly diagnosed advanced prostate cancer, drawing criticism from the Institute of Cancer Research (ICR).  The UK cost-effectiveness body first turned down Zytiga (abiraterone acetate) for this use in June 2020, but said four …

NICE second Zytiga rejection ‘shows need for flexible pricing models’ Read More »

ViewPoints Interview: Q BioMed’s Denis Corin Shares Insights on the Agreement to Serve US Department of Defense and Veterans Affairs

In an interview with PharmaShots, Denis Corin, Chief Executive Officer and Chairman of the Board at Q BioMed share his views on the supply agreement for Strontium89 with the US Department of Defense and Veterans Affairs. Shots: BioMed has signed a 5-year agreement to commercially serve the US Department of Veterans Affairs (VA) and Department …

ViewPoints Interview: Q BioMed’s Denis Corin Shares Insights on the Agreement to Serve US Department of Defense and Veterans Affairs Read More »

Prostate Cancer Drug Development Summit

The inaugural Prostate Cancer Drug Development Summit is the only industry-led meeting uniting large pharma, biotech and pioneering academics with the ambitious objective of accelerating the clinical development of safe and effective therapies to treat prostate cancer. With sessions on both early and advanced stages of prostate cancer (Non-Metastatic Castrate-Resistant Prostate Cancer (nmCRPC) and Metastatic Castrate-Resistant Prostate Cancer (mCRPC), this is a conversation not …

Prostate Cancer Drug Development Summit Read More »

Bayer props up sagging radionuclide business with Noria acquisition

Bayer has agreed to buy Noria Therapeutics and its subsidiary PSMA Therapeutics, adding to its pipeline of radionuclide drugs for cancer as sales of its lead product in the category – Xofigo – continue to decline.  Just over three years ago, Bayer was forced to concede that its blockbuster expectations for Xofigo (radium Ra 223 …

Bayer props up sagging radionuclide business with Noria acquisition Read More »

ASCO21: Novartis’ prostate cancer radiotherapy extends survival

Novartis’ big investment in radiopharmaceuticals for cancer seems to have paid off, after lead candidate 177Lu-PSMA-617 helped men with advanced prostate cancer and few treatment options live longer in a phase 3 trial. New data from the VISION study showed that 177Lu-PSMA-617 on top of standard care reduced the risk of death by 38% compared …

ASCO21: Novartis’ prostate cancer radiotherapy extends survival Read More »

Novartis radiopharmaceutical improves survival in key prostate cancer study

Novartis reported Phase 3 study results for a targeted radiation therapy showing that treatment helped patients with advanced prostate cancer live longer. The company will present data from this pivotal study during the annual meeting of the American Society of Clinical Oncology.

Tomato Sauce Put to the Test for Prostate Cancer

What happened when cancer patients were given three quarters of a cup of canned tomato sauce every day for three weeks? “Occasionally…positive things happen in the field of cancer prevention science to popular, good-tasting foods.” Cruciferous vegetables like broccoli are wonderful, but they may be “a hard food for the public to swallow.” By contrast, …

Tomato Sauce Put to the Test for Prostate Cancer Read More »

Lycopene Supplements Put to the Test

High doses of lycopene—the red pigment in tomatoes—were put to the test to see if it could prevent precancerous prostate lesions from turning into full-blown cancer. Back in 1980s, the Adventist Health Study found “strong protective relationships” against prostate cancer with increasing consumption of legumes, citrus, dried fruit, nuts, and tomatoes. In the 1990s, a …

Lycopene Supplements Put to the Test Read More »

NICE rejects J&J’s prostate cancer drug Erleada in initial guidance

NICE has rejected Johnson & Johnson’s oral prostate cancer drug Erleada (apalutamide) in patients with hormone-relapsed or hormone sensitive disease in first draft guidance. The cost-effectiveness body is assessing Erleada, plus androgen deprivation therapy (ADT), for prostate cancer in adults who have hormone-relapsed non-metastatic disease at high risk of metastasising and hormone-sensitive metastatic disease. Hormone …

NICE rejects J&J’s prostate cancer drug Erleada in initial guidance Read More »

Are Avocados Associated with Greater Risk or Reduced Risk of Cancer?

Avocado consumption can improve artery function, but what effect might guacamole have on cancer risk? In my last video about avocados, The Effects of Avocados and Red Wine on Meal-Induced Inflammation, I described their anti-inflammatory effects and cholesterol- and triglyceride-lowering effects, but what about the Are Avocados Good for You? video I did years ago …

Are Avocados Associated with Greater Risk or Reduced Risk of Cancer? Read More »

J&J decides against Erleada+Zytiga combination prostate cancer filing

Johnson & Johnson won’t be filing a prostate cancer therapy combining its Erleada and Zytiga drugs with regulators, after a phase 3 trial showed it didn’t improve survival compared with Zytiga alone. Zytiga is the older of the two drugs and was used in the active control arm of the ACIS study, which tested the …

J&J decides against Erleada+Zytiga combination prostate cancer filing Read More »

ViewPoints Interview: Myriad Genetics’ Dr. Todd D. Cohen Shares Insight on Prolaris Test’s Ability to Guide Prostate Cancer Treatment

In an interview with PharmaShots, Dr. Todd D. Cohen, M.D., VP Medical Affairs and Medical Director of Urology at Myriad Genetics shared his views on the ability of a biomarker test to predict which men with aggressive prostate cancer will benefit from advanced hormonal therapy and which men with lower-risk prostate cancer can safely avoid such …

ViewPoints Interview: Myriad Genetics’ Dr. Todd D. Cohen Shares Insight on Prolaris Test’s Ability to Guide Prostate Cancer Treatment Read More »

Novartis’ radioligand therapy meets phase 3 prostate cancer trial target

Novartis’ radioligand therapy Lu-PSMA-617 has met its target in prostate cancer, as its $2.1 billion acquisition of specialist pharma Endocyte looks to have been justified.  The big Swiss pharma added this drug to its pipeline after it swooped for Endocyte and so far it looks like a good piece of business, with potential blockbuster sales …

Novartis’ radioligand therapy meets phase 3 prostate cancer trial target Read More »

NICE says no to AZ’s Lynparza for prostate cancer

NHS patients in England will not be able to get access to AstraZeneca’s PARP inhibitor Lynparza if they have BRCA-positive advance prostate cancer, according to draft guidance from NICE. The cost-effectiveness agency is assessing use of Lynparza (olaparib) in patients with tumours that carry BRCA1 or BRCA2 mutations who have previously been treated with the …

NICE says no to AZ’s Lynparza for prostate cancer Read More »

Treating Advanced Prostate Cancer with Diet

Dr. Dean Ornish showed that a plant-based diet and lifestyle program could apparently reverse the progression of prostate cancer for early stage, localized, watch-and-wait cancer. What about for more advanced stage life-threatening disease? Dr. Dean Ornish showed that a plant-based diet and lifestyle program could apparently reverse the progression of prostate cancer by making men’s …

Treating Advanced Prostate Cancer with Diet Read More »

A USD 4.2 Billion Myovant/ Pfizer Deal; Audentes Therapeutics’ ASPIRO Trial Free to Proceed; First Generic of Drug for Severe Hypoglycemia Gets Approval; Teleflex Acquires Z-Medica

A USD 4.2 Billion Myovant/ Pfizer Deal Myovant Sciences have decided to put their forces and efforts together to advance the Prostate cancer market as they announced their partnership deal to develop and market relugolix for prostate cancer and women’s health.  Relugolix is a once-daily, oral gonadotropin-release hormone (GnRH) receptor antagonist. If approved, it will …

A USD 4.2 Billion Myovant/ Pfizer Deal; Audentes Therapeutics’ ASPIRO Trial Free to Proceed; First Generic of Drug for Severe Hypoglycemia Gets Approval; Teleflex Acquires Z-Medica Read More »

Sharing experiences to level the healthcare playing field

Amanda Barrell speaks to Alfred Samuels on his experience of prostate cancer and diversifying clinical trials to include the Black, Asian and minority ethnic (BAME) community. Alfred Samuels’ stage 4 metastatic prostate cancer brought his 30-year career, which had seen him travel the world with the likes of Beyoncé, Oasis, and Bob Dylan, to a …

Sharing experiences to level the healthcare playing field Read More »

Can Soy Prevent and Treat Prostate Cancer?

As I discuss in my video The Role of Soy Foods in Prostate Cancer Prevention and Treatment, a compilation of 13 observational studies on soy food consumption and the risk of prostate cancer found that soy foods appear to be “protective.” What are observational studies? As opposed to interventional studies, in observational studies, researchers observe …

Can Soy Prevent and Treat Prostate Cancer? Read More »

Fermented or Unfermented Soy?

As you can see at the start of my video Fermented or Unfermented Soy Foods for Prostate Cancer Prevention?, there is an enormous variation in the rates of prostate cancer around the globe, with among the highest rates in the United States and lowest rates in Asia—though that may be changing. The largest increase in …

Fermented or Unfermented Soy? Read More »

Food Combining for Prostate Cancer

What would happen if you secretly gave cancer patients four of the healthiest foods? In my video Pomegranate vs. Placebo for Prostate Cancer, I discussed how pomegranate pills appeared useless in the treatment for prostate cancer, and the same disappointing results were seen with a pomegranate beverage, but that was just a pomegranate extract as …

Food Combining for Prostate Cancer Read More »

What Explains the Egg-Cancer Connection

The reason egg consumption is associated with elevated cancer risk may be the TMAO, considered the “smoking gun” of microbiome-disease interactions. “We are walking communities comprised not only of a Homo sapiens host, but also of trillions of symbiotic commensal microorganisms within the gut and on every other surface of our bodies.” There are more …

What Explains the Egg-Cancer Connection Read More »